Several factors influence whether this combined approach might be suitable, including the type of hormone therapy, your baseline health, and how your body responds to each treatment
Since knowledge is power, especially when it comes to your health, weve broken down the science, weight-loss stats, and side effects for each of these wonder drugs
[1] [2] Whilst cardiovascular benefits have been demonstrated in clinical trialsincluding reduced risk of major adverse cardiovascular eventssome patients report experiencing a racing heart or palpitations after starting treatment
No association between GLP-1 and weight loss Ansh Labs Oxyntomodulin ELISA (AL-139) and Ansh Labs Glicentin ELISA (AL-185) References Pocai A
Historically, no, but qualifying Medicare beneficiaries can get coverage for Wegovy from July 1, 2026, until December 31, 2027, via the new Medicare GLP-1 Bridge program